SG Americas Securities LLC Has $83,000 Holdings in Perspective Therapeutics, Inc. (NYSE:CATX)

SG Americas Securities LLC boosted its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 41.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 26,088 shares of the company’s stock after buying an additional 7,627 shares during the period. SG Americas Securities LLC’s holdings in Perspective Therapeutics were worth $83,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. FMR LLC grew its stake in shares of Perspective Therapeutics by 3,994.9% in the 3rd quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after buying an additional 5,370,392 shares in the last quarter. Nicholson Wealth Management Group LLC bought a new position in shares of Perspective Therapeutics in the third quarter valued at about $21,390,000. State Street Corp raised its holdings in shares of Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after buying an additional 1,192,812 shares during the last quarter. Hills Bank & Trust Co acquired a new stake in Perspective Therapeutics in the third quarter worth about $13,722,000. Finally, Janus Henderson Group PLC grew its position in shares of Perspective Therapeutics by 8.0% during the 3rd quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock worth $64,014,000 after buying an additional 355,685 shares during the period. Institutional investors and hedge funds own 54.66% of the company’s stock.

Insider Activity

In other Perspective Therapeutics news, CEO Johan M. Spoor bought 14,500 shares of Perspective Therapeutics stock in a transaction that occurred on Monday, November 25th. The stock was acquired at an average cost of $3.78 per share, for a total transaction of $54,810.00. Following the completion of the transaction, the chief executive officer now directly owns 152,072 shares in the company, valued at $574,832.16. This represents a 10.54 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Heidi Henson purchased 25,975 shares of the company’s stock in a transaction on Wednesday, December 4th. The shares were purchased at an average cost of $3.85 per share, with a total value of $100,003.75. Following the purchase, the director now owns 25,975 shares of the company’s stock, valued at approximately $100,003.75. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 67,570 shares of company stock worth $256,789 over the last 90 days. 3.52% of the stock is currently owned by corporate insiders.

Perspective Therapeutics Price Performance

Shares of Perspective Therapeutics stock opened at $3.11 on Friday. Perspective Therapeutics, Inc. has a 52 week low of $2.70 and a 52 week high of $19.05. The stock has a 50 day moving average price of $3.40 and a two-hundred day moving average price of $8.92.

Perspective Therapeutics (NYSE:CATX) last posted its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The company had revenue of $0.37 million for the quarter. As a group, sell-side analysts predict that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on CATX. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a report on Wednesday, February 5th. UBS Group initiated coverage on Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price objective on the stock. Oppenheimer reduced their target price on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, November 22nd. Royal Bank of Canada reiterated an “outperform” rating and issued a $16.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. Finally, Bank of America cut Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the company from $24.00 to $5.00 in a research note on Monday, November 25th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $15.14.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.